Reneo Pharmaceuticals, Inc.
NASDAQ:RPHM
18.2 (USD) • At close October 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.525 | 0.529 | 0.05 | 0.037 | 0.034 |
| Gross Profit
| -0.525 | -0.529 | -0.05 | -0.037 | -0.034 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 56.613 | 37.705 | 28.169 | 15.944 | 13.097 |
| General & Administrative Expenses
| 25.79 | 16.143 | 11.649 | 3.608 | 2.376 |
| Selling & Marketing Expenses
| 26.436 | 0 | 0 | 0 | 0 |
| SG&A
| 25.79 | 16.143 | 11.649 | 3.608 | 2.376 |
| Other Expenses
| 0.65 | 1.893 | 0.048 | 0.087 | 3.037 |
| Operating Expenses
| 83.053 | 53.848 | 39.818 | 19.552 | 15.473 |
| Operating Income
| -83.053 | -53.848 | -39.818 | -19.552 | -15.473 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.665 | 1.893 | 0.048 | 0.087 | 3.037 |
| Income Before Tax
| -77.388 | -51.955 | -39.77 | -19.465 | -12.436 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.65 | -1.893 | -0.187 | -0.169 | -0.138 |
| Net Income
| -77.388 | -50.062 | -39.77 | -19.465 | -12.436 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -25.23 | -2.04 | -2.19 | -0.8 | -1.6 |
| EPS Diluted
| -25.23 | -2.04 | -2.19 | -0.8 | -1.6 |
| EBITDA
| -82.233 | -53.76 | -39.768 | -19.515 | -15.439 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |